This Lichen planus - Pipeline Insight, 2021 provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Lichen planus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Lichen planus is a T cell-mediated autoimmune disorder, in which inflammatory cells attack an unknown protein within the skin and mucosal keratinocytes. There are several clinical types of lichen planus that share similar features on histopathology. Lichen planus affects about one in one hundred people worldwide, mostly affecting adults over the age of 40 years. About half those affected have oral lichen planus, which is more common in women than in men. About 10% have lichen planus of the nails. Symptoms of lichen planus depend on the part or parts of your body affected. The most common symptoms are shiny red or purple bumps on skin. Lichen planus inside mouth looks like lacy patches of tiny white dots. Lichen planus may appear on a few, or all, of your fingernails and toenails. Thinning, ridges, splitting, and nail loss are signs of the condition. To make sure of the diagnosis, the doctor will perform a biopsy. He or she will remove mouth mucosa, or a small piece of skin, and send it to be examined it under a microscope. Lichen planus has no cure, but different treatments can help relieve symptoms and speed healing.
Lichen planus - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lichen planus pipeline landscape is provided which includes the disease overview and Lichen planus treatment guidelines. The assessment part of the report embraces, in depth Lichen planus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lichen planus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Lichen planus R&D. The therapies under development are focused on novel approaches to treat/improve Lichen planus.
This segment of the Lichen planus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Rivelin-CLO: AFYX Therapeutics
Rivelin is a muco-adhesive two layered patch that delivers a pharmaceutical product (such as clobetasol) directly to wet tissue surfaces. Rivelin utilizes a unique patch technology that adheres to mucosal surfaces for extended periods, facilitating uni-directional delivery of a pharmaceutical agent to the target site of action impacting disease progression, while limiting delivery to surrounding areas. Rivelin-CLO patch, met its primary endpoint and multiple secondary endpoints in a Phase IIb clinical study for the treatment of oral lichen planus.
There are approx. 6+ key companies which are developing the therapies for Lichen planus. The companies which have their Lichen planus drug candidates in the most advanced stage, i.e. Phase III include, AFYX Therapeutics.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lichen planus therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lichen planus drugs.
Geography Covered
- Global coverage
Lichen planus Understanding
Lichen planus: Overview
Lichen planus is a T cell-mediated autoimmune disorder, in which inflammatory cells attack an unknown protein within the skin and mucosal keratinocytes. There are several clinical types of lichen planus that share similar features on histopathology. Lichen planus affects about one in one hundred people worldwide, mostly affecting adults over the age of 40 years. About half those affected have oral lichen planus, which is more common in women than in men. About 10% have lichen planus of the nails. Symptoms of lichen planus depend on the part or parts of your body affected. The most common symptoms are shiny red or purple bumps on skin. Lichen planus inside mouth looks like lacy patches of tiny white dots. Lichen planus may appear on a few, or all, of your fingernails and toenails. Thinning, ridges, splitting, and nail loss are signs of the condition. To make sure of the diagnosis, the doctor will perform a biopsy. He or she will remove mouth mucosa, or a small piece of skin, and send it to be examined it under a microscope. Lichen planus has no cure, but different treatments can help relieve symptoms and speed healing.
Lichen planus - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lichen planus pipeline landscape is provided which includes the disease overview and Lichen planus treatment guidelines. The assessment part of the report embraces, in depth Lichen planus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lichen planus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Lichen planus R&D. The therapies under development are focused on novel approaches to treat/improve Lichen planus.
Lichen planus Emerging Drugs Chapters
This segment of the Lichen planus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lichen planus Emerging Drugs
Rivelin-CLO: AFYX Therapeutics
Rivelin is a muco-adhesive two layered patch that delivers a pharmaceutical product (such as clobetasol) directly to wet tissue surfaces. Rivelin utilizes a unique patch technology that adheres to mucosal surfaces for extended periods, facilitating uni-directional delivery of a pharmaceutical agent to the target site of action impacting disease progression, while limiting delivery to surrounding areas. Rivelin-CLO patch, met its primary endpoint and multiple secondary endpoints in a Phase IIb clinical study for the treatment of oral lichen planus.
Lichen planus: Therapeutic Assessment
This segment of the report provides insights about the different Lichen planus drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Lichen planus
There are approx. 6+ key companies which are developing the therapies for Lichen planus. The companies which have their Lichen planus drug candidates in the most advanced stage, i.e. Phase III include, AFYX Therapeutics.
Phases
This report covers around 6+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Lichen planus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Lichen planus: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lichen planus therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lichen planus drugs.
Lichen planus Report Insights
- Lichen planus Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Lichen planus Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Lichen planus drugs?
- How many Lichen planus drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lichen planus?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Lichen planus therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Lichen planus and their status?
- What are the key designations that have been granted to the emerging drugs?
Table of Contents
IntroductionExecutive Summary
Lichen planus: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Rivelin-CLO: AFYX Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Preclinical stage products
- Comparative Analysis
LP-310: Lipella Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Lichen planus Key Companies
Lichen planus Key Products
Lichen planus- Unmet Needs
Lichen planus- Market Drivers and Barriers
Lichen planus- Future Perspectives and Conclusion
Lichen planus Analyst Views
Lichen planus Key Companies
AppendixList of Tables
Table 1 Total Products for Lichen planus
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Lichen planus
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Novartis
- Amgen
- Kiniksa Pharmaceuticals
- AFYX Therapeutics
- Regeneus
